Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
616 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleIparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 26
- Run by
- Tongji Hospital
See details and how to joinNCT06954116 - No phaseTaking peoplePrecision Navigation to Improve Community Cancer Screening Participation
- Where
- Huaihua, Shaoyang, Yongzhou
- Age
- 45 years to 74 years
- People
- 1,500
- Run by
- Hunan Cancer Hospital
See details and how to joinNCT07676383 - Phase 2/3Taking peopleCombination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma
- Where
- Beijing
- People
- 80
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT02851784 - No phaseNot yet taking people in ChinaHeterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026)
- Where
- Nanjing
- Age
- 18 years and over
- People
- 2,658
- Run by
- Zhongda Hospital
See details and how to joinNCT07824765 - Phase 1/2Taking peopleA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Where
- Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lishui, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06427941 · EU 2025-524136-19-00 - Phase 3Not yet taking people in ChinaJS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
- Where
- Harbin, Shanghai
- Age
- 18 years to 75 years
- People
- 560
- Run by
- Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT07823348 - Phase 4Taking peopleA Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 32
- Run by
- Xianglin Yuan
See details and how to joinNCT07619235 - Phase 2Taking peopleIparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 35
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07776080 - No phaseTaking peopleA Cohort Study (Risk Prediction of HCC in Patients With Chronic Liver Disease)
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 15,000
- Run by
- Cai Qingxian
See details and how to joinNCT07820644 - Phase 2Taking peoplePhase 2 Study of WGI-0301 for Advanced HCC
- Where
- Changsha, Chengdu, Hangzhou, Harbin, Nanchang, Shanghai, Wuhan
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Zhejiang Haichang Biotech Co., Ltd.
See details and how to joinNCT06309485 - Phase 2Taking peopleOral Fecal Microbiota Transplantation in Advanced Hepatocellular Carcinoma After Progression on ICI-TKI Therapy
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Xu Yong, MD
See details and how to joinNCT06563947 - No phaseTaking peopleGPC3-Targeted PET/CT in Hepatocellular Carcinoma
- Where
- Xiamen
- Age
- 18 years to 90 years
- People
- 40
- Run by
- The First Affiliated Hospital of Xiamen University
See details and how to joinNCT07677774 - No phaseTaking peopleEffect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
- Where
- Yangzhou
- Age
- 18 years to 80 years
- People
- 30
- Run by
- Northern Jiangsu People's Hospital
See details and how to joinNCT07811687 - Phase 3Not yet taking people in ChinaZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
- Where
- Nanjing
- Age
- 18 years and over
- People
- 600
- Run by
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
See details and how to joinNCT07813572 - No phaseTaking peopleProstate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
- Where
- Hefei, Qingdao, Tianjin
- Age
- 18 years to 80 years
- People
- 500
- Run by
- Tianjin Medical University
See details and how to joinNCT06690970 - Phase 2Taking peopleAnlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07806292 - Phase 2Taking peopleIparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
- Where
- Tianjin
- Age
- 18 years and over
- People
- 20
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07801287 - Phase 2Taking peoplePULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
- Where
- Chengdu
- Age
- 18 years to 75 years
- People
- 64
- Run by
- Wang Xin
See details and how to joinNCT07463248 - No phaseTaking peopleGPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma
- Where
- Beijing
- Age
- 18 years and over
- People
- 100
- Run by
- Peking University First Hospital
See details and how to joinNCT07795437 - No phaseTaking peopleIRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus
- Where
- Tianjin
- Age
- 18 years to 75 years
- People
- 60
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07799922 - Phase 2Taking peopleStudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
- Where
- Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanjing, Shanghai
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT05727176 · EU 2023-503665-39-00 - Phase 3Taking peopleSBRT Versus Surgical Resection for Small HCC
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 390
- Run by
- Sun Yat-sen University
See details and how to joinNCT07381660 - Phase 2Taking peopleLiposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer
- Where
- Nanjing
- Age
- 18 years to 80 years
- People
- 31
- Run by
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
See details and how to joinNCT07797816 - Phase 1Taking peopleA Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma
- Where
- Beijing
- Age
- 18 years to 70 years
- People
- 21
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07557251 - No phaseTaking peopleHCCANANO-HOPE1: IRE After Chemotherapy for Locally Advanced Unresectable Perihilar Cholangiocarcinoma
- Where
- Tianjin
- Age
- 18 years to 75 years
- People
- 60
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07795619